Corpus overview


Overview

MeSH Disease

COVID-19 (18)

Pneumonia (18)

Lymphopenia (18)

Fever (7)

Leukopenia (3)


HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 18
    records per page




    COVID-19 MESHD and pregnancy: An umbrella review of clinical presentation, vertical transmission, and maternal and perinatal outcomes

    Authors: Agustin Ciapponi; Ariel Bardach; Daniel Comande; Mabel Berrueta; Fernando J Argento; Federico Rodriguez Cairoli; Natalia Zamora; Victoria Santa Maria; Xu Xiong; Sabra Zaraa; Agustina Mazzoni; Pierre Buekens

    doi:10.1101/2021.04.29.21256327 Date: 2021-05-02 Source: medRxiv

    Background We conducted an overview of systematic reviews (SRs) summarizing the best evidence regarding the effect of COVID-19 MESHD on maternal and child health following Cochrane methods and PRISMA statement for reporting (PROSPERO-CRD42020208783). Methods We searched literature databases and COVID-19 MESHD research websites from January to October 2020. We selected relevant SRs reporting adequate search strategy, data synthesis, risk of bias assessment, and/or individual description of included studies describing COVID-19 MESHD and pregnancy outcomes. Pair of reviewers independently selected studies through COVIDENCE web-software, performed the data extraction, and assessed its quality through the AMSTAR-2 tool. Discrepancies were resolved by consensus. Each SR's results were synthesized and for the most recent, relevant, comprehensive, and with the highest quality, by predefined criteria, we presented GRADE evidence tables. Results We included 66 SRs of observational studies out of 608 references retrieved and most (61/66) had "critically low" overall quality. We found a relatively low degree of primary study overlap across SRs. The most frequent COVID-19 MESHD clinical findings during pregnancy were fever (28-100%), mild respiratory symptoms (20-79%), raised C-reactive protein HGNC (28-96%), lymphopenia MESHD (34-80%), and pneumonia MESHD signs in diagnostic imaging (7-99%). The most frequent maternal outcomes were C-section (23-96%) and preterm delivery (14-64%). Most of their babies were asymptomatic (16-93%) or presented fever (0-50%), low birth weight MESHD (5-43%) or preterm delivery (2-69%). The odds ratio (OR) of receiving invasive ventilation for COVID-19 MESHD versus non- COVID-19 MESHD pregnant women was 1.88 (95% Confidence Interval [CI] 1.36-2.60) and the OR that their babies were admitted to neonatal intensive care unit was 3.13 (95%CI 2.05-4.78). The risk of congenital transmission or via breast milk was estimated to be low, but close contacts may carry risks. Conclusion This comprehensive overview supports that pregnant women with COVID-19 MESHD may be at increased risk of adverse pregnancy and birth outcomes and low risk of congenital transmission.

    Viral Shedding Time of SARS-CoV-2 and the Factors Involved: A Retrospective Observational Study

    Authors: Guixian Wu; Ling Lin; Susu He; Qian Chen; Xiaomai Wu; Shuangquan Yan; Yongpo Jiang; Weijia Pan; Dongqin Lv

    doi:10.21203/rs.3.rs-154418/v1 Date: 2021-01-25 Source: ResearchSquare

    Background: In December 2019, the discovery of the novel coronavirus was first reported in Wuhan, China, which subsequently and rapidly spread throughout the country and worldwide, resulting in a pandemic.After a year of intense research, our knowledge of the new coronaviruses has gradually improved; however, knowledge regarding the time of their complete clearance from the body and the factors influencing clearance are currently inadequate. Results: We conducted a retrospective observational study comprising 135 patients above the age of 18 years with a confirmed diagnosis of  COVID-19 MESHD pneumonia MESHD, who were admitted to the Public Health Center of Taizhou Hospital of Zhejiang Province, Zhejiang University from January 23, 2020, to March 11 HGNC, 2020. The findings regarding the duration of the infection from the time of onset to the time of being asymptomatic (whichever was observed first) indicated that novel coronaviruses were cleared from the respiratory tract in a maximum of 84 days and a minimum of 1 day with a median clearance time (quartile) of 20 (13, 30) days. Moreover, viruses were cleared from the digestive tract in a maximum of 72 days and a minimum of 5 days with a median clearance time (quartile) of 25 (20.75, 31) days. The viral shedding time of SARS in the digestive tract was found to be longer than that in the respiratory tract (p = 0.03). Severe disease (P < 0.001), advanced age (P < 0.001), lymphopenia MESHD (P = 0.01) and elevated CRP HGNC (P = 0.036) were significantly associated with longer clearance time in the respiratory tract. Gender (P = 0.754), novel coronavirus antibodies (P = 0.75), and antibiotic use (P = 0.093) were not associated with the time span required for the novel coronavirus to be cleared from the respiratory tract. Conclusions: Independent risk factors for the longer clearance time of novel coronaviruses in the digestive tract versus that in the respiratory tract were compared. Severe disease MESHD, advanced age, lymphopenia MESHD, and elevated CRP HGNC were determined to be factors prolonging the clearance of novel coronaviruses.

    A Large-Scale Clinical Validation Study Using nCapp Cloud Plus Terminal by Frontline Doctors for the Rapid Diagnosis of COVID-19 MESHD and COVID-19 MESHD pneumonia in China

    Authors: Dawei Yang; Tao Xu; Xun Wang; Deng Chen; Ziqiang Zhang; Lichuan Zhang; Jie Liu; Kui Xiao; Li Bai; Yong Zhang; Lin Zhao; Lin Tong; Chaomin Wu; Yaoli Wang; Chunling Dong; Maosong Ye; Yu Xu; Zhenju Song; Hong Chen; Jing Li; Jiwei Wang; Fei Tan; Hai Yu; Jian Zhou; Jinming Yu; Chunhua Du; Hongqing Zhao; Yu Shang; Linian Huang; Jianping Zhao; Yang Jin; Charles A. Powell; Yuanlin Song; Chunxue Bai

    doi:10.1101/2020.08.07.20163402 Date: 2020-08-11 Source: medRxiv

    Background The outbreak of coronavirus disease 2019 MESHD ( COVID-19 MESHD) has become a global pandemic acute infectious disease MESHD, especially with the features of possible asymptomatic carriers and high contagiousness. It causes acute respiratory distress syndrome MESHD and results in a high mortality rate if pneumonia is involved. Currently, it is difficult to quickly identify asymptomatic cases or COVID-19 MESHD patients with pneumonia MESHD due to limited access to reverse transcription-polymerase chain reaction (RT-PCR) nucleic acid tests and CT scans, which facilitates the spread of the disease at the community level, and contributes to the overwhelming of medical resources in intensive care units. Goal This study aimed to develop a scientific and rigorous clinical diagnostic tool for the rapid prediction of COVID-19 MESHD cases based on a COVID-19 MESHD clinical case database in China, and to assist global frontline doctors to efficiently and precisely diagnose asymptomatic COVID-19 MESHD patients and cases who had a false-negative RT-PCR test result. Methods With online consent, and the approval of the ethics committee of Zhongshan Hospital Fudan Unversity (approval number B2020-032R) to ensure that patient privacy is protected, clinical information has been uploaded in real-time through the New Coronavirus Intelligent Auto-diagnostic Assistant Application of cloud plus terminal (nCapp) by doctors from different cities (Wuhan, Shanghai, Harbin, Dalian, Wuxi, Qingdao, Rizhao, and Bengbu) during the COVID-19 MESHD outbreak in China. By quality control and data anonymization on the platform, a total of 3,249 cases from COVID-19 MESHD high-risk groups were collected. These patients had SARS-CoV-2 RT-PCR test results and chest CT scans, both of which were used as the gold standard for the diagnosis of COVID-19 MESHD and COVID-19 MESHD pneumonia MESHD. In particular, the dataset included 137 indeterminate cases who initially did not have RT-PCR tests and subsequently had positive RT-PCR results, 62 suspected cases who initially had false-negative RT-PCR test results and subsequently had positive RT-PCR results, and 122 asymptomatic cases who had positive RT-PCR test results, amongst whom 31 cases were diagnosed. We also integrated the function of a survey in nCapp to collect user feedback from frontline doctors. Findings We applied the statistical method of a multi-factor regression model to the training dataset (1,624 cases) and developed a prediction model for COVID-19 MESHD with 9 clinical indicators that are fast and accessible: 'Residing or visiting history in epidemic regions', 'Exposure history to COVID-19 MESHD patient', 'Dry cough', 'Fatigue', 'Breathlessness', 'No body temperature decrease after antibiotic treatment', 'Fingertip blood oxygen saturation<=93%', ' Lymphopenia' MESHD, and ' C-reactive protein HGNC ( CRP HGNC) increased'. The area under the receiver operating characteristic (ROC) curve (AUC) for the model was 0.88 (95% CI: 0.86, 0.89) in the training dataset and 0.84 (95% CI: 0.82, 0.86) in the validation dataset (1,625 cases). To ensure the sensitivity of the model, we used a cutoff value of 0.09. The sensitivity and specificity of the model were 98.0% (95% CI: 96.9%, 99.1%) and 17.3% (95% CI: 15.0%, 19.6%), respectively, in the training dataset, and 96.5% (95% CI: 95.1%, 98.0%) and 18.8% (95% CI: 16.4%, 21.2%), respectively, in the validation dataset. In the subset of the 137 indeterminate cases who initially did not have RT-PCR tests and subsequently had positive RT-PCR results, the model predicted 132 cases, accounting for 96.4% (95% CI: 91.7%, 98.8%) of the cases. In the subset of the 62 suspected cases who initially had false-negative RT-PCR test results and subsequently had positive RT-PCR results, the model predicted 59 cases, accounting for 95.2% (95% CI: 86.5%, 99.0%) of the cases. Considering the specificity of the model, we used a cutoff value of 0.32. The sensitivity and specificity of the model were 83.5% (95% CI: 80.5%, 86.4%) and 83.2% (95% CI: 80.9%, 85.5%), respectively, in the training dataset, and 79.6% (95% CI: 76.4%, 82.8%) and 81.3% (95% CI: 78.9%, 83.7%), respectively, in the validation dataset, which is very close to the published AI model. The results of the online survey 'Questionnaire Star' showed that 90.9% of nCapp users in WeChat mini programs were 'satisfied' or 'very satisfied' with the tool. The WeChat mini program received a significantly higher satisfaction rate than other platforms, especially for 'availability and sharing convenience of the App' and 'fast speed of log-in and data entry'. Discussion With the assistance of nCapp, a mobile-based diagnostic tool developed from a large database that we collected from COVID-19 MESHD high-risk groups in China, frontline doctors can rapidly identify asymptomatic patients and avoid misdiagnoses of cases with false-negative RT-PCR results. These patients require timely isolation or close medical supervision. By applying the model, medical resources can be allocated more reasonably, and missed diagnoses can be reduced. In addition, further education and interaction among medical professionals can improve the diagnostic efficiency for COVID-19 MESHD, thus avoiding the transmission of the disease from asymptomatic patients at the community level.

    Clinical Characteristics of 10 Children With a Pediatric Inflammatory Multisystem Syndrome Associated with COVID-19 MESHD In Iran

    Authors: Leila Shahbaznejad; Mohammad Reza Navaifar; Ali Abbaskhanian; Fatemeh Hosseinzadeh; Golnar Rahimzadeh; Mohammad Sadegh Rezai

    doi:10.21203/rs.3.rs-51157/v3 Date: 2020-07-30 Source: ResearchSquare

    Background: Although symptoms and signs of COVID-19 MESHD ( Coronavirus disease 2019 MESHD) in children are milder than adults, there are reports of more severe cases which were defined as pediatric inflammatory multisystem syndrome MESHD ( PIMS MESHD). The purpose of this report was to describe the possible association between COVID-19 MESHD and PIMS in children.  Methods: From 28 March to 24 June 2020, 10 febrile children were admitted with COVID-19 MESHD infection showing characteristics of PIMS in Buali tertiary hospital of Sari, in Mazandaran province, northern Iran. Demographic and clinical characteristics, laboratory and imaging findings, and therapeutic modalities were recorded and analyzed. Results: The mean age of the patients was 5.37±3.9 years (13 months to 12 years). Six of them were boys. Kawasaki disease MESHD, myocarditis MESHD, toxic shock syndrome MESHD, appendicitis MESHD, sepsis MESHD, urosepsis, prolonged febrile seizure MESHD, acute hemorrhagic edema MESHD of infancy, and COVID-19 MESHD-related pneumonia MESHD were their first presentation. All of them had increased C-reactive protein HGNC levels, and most of them had elevated erythrocyte sedimentation rate, lymphopenia, anemia MESHD, and hypoalbuminemia MESHD. Three of them had thrombocytopenia MESHD(PLT<106). Six of them were serologically or polymerase chain reaction positive for COVID-19 MESHD, and 4 of them were diagnosed as COVID-19 MESHD just by chest computed tomography scan. Most of the patients improved without a residual sequel, except one who died with multiorgan failure MESHD and another case was discharged with a giant coronary aneurysm MESHD.Conclusion: Children with COVID-19 MESHD may present symptoms similar to Kawasaki disease MESHD and inflammatory syndromes. PIMS should be considered in children with fever MESHD, rash MESHD, seizure MESHD, cough, tachypnea MESHD, and gastrointestinal symptoms such as vomiting MESHD, diarrhea MESHD, and abdominal pain MESHD.

    Viral shedding and immunological features of children COVID-19 MESHD patients

    Authors: Yang Yang; Haixia Zheng; Ling Peng; Jinli Wei; Yanrong Wang; Hexiao Li; Bo Peng; Shisong Fang; Mingxia Zhang; Yanjie Li; Hui Liu; Kai Feng; Li Xing; Jun Wang; Mengli Cao; Fuxiang Wang; Lei Liu; Yingxia Liu; Jing Yuan

    doi:10.21203/rs.3.rs-48544/v2 Date: 2020-07-24 Source: ResearchSquare

    Background SARS-CoV-2 could infect people at all ages, and the viral shedding and immunological features of children COVID-19 MESHD patients were analyzed.Methods Epidemiological information and clinical data were collected from 35 children patients. Viral RNAs in respiratory and fecal samples were detected. Plasma of 11 patients were collected and measured for 48 cytokines.Results 40% (14/35) of the children COVID-19 MESHD patients showed asymptomatic infections, while pneumonia MESHD shown by CT scan occurred in most of the cases (32/35, 91.43%). Elevated LDH, AST HGNC, CRP HGNC, neutropenia MESHD, leukopenia MESHD, lymphopenia MESHD and thrombocytopenia MESHD occurred in some cases, and CD4 HGNC and CD8 HGNC counts were normal. A total of 22 cytokines were significantly higher than the healthy control, and IP-10 HGNC, IFN-α2 HGNC of them in children were significantly lower than the adult patients. Meanwhile, MCP-3 HGNC, HGF HGNC, MIP-1α HGNC, and IL-1ra HGNC were similar or lower than healthy control, while significantly lower than adult patients. Viral RNAs were detected as early as the first day after illness onset (d.a.o) in both the respiratory and fecal samples. Viral RNAs decreased as the disease progression and mostly became negative in respiratory samples within 18 d.a.o, while maintained relatively stable during the disease progression and still detectable in some cases during 36~42 d.a.o. Conclusion COVID-19 MESHD in children was mild, and asymptomatic infection was common. Immune responses were relatively normal in children COVID-19 MESHD patients. Cytokine storm also occurred in children patients, while much weaker than adult patients. Positive rate of viral RNAs in fecal samples was high, and profile of viral shedding were different between respiratory and gastrointestinal tract.

    Recombinant interleukin-2 HGNC stimulates lymphocyte recovery in severe patients with COVID-19 MESHD

    Authors: Meng‘en Zhu; Qian Wang; Shaoqiong Zhou; Bin Wang; Li Ke; Ping He

    doi:10.21203/rs.3.rs-40006/v1 Date: 2020-07-03 Source: ResearchSquare

    Object: A recently developing pneumonia MESHD called COVID-19 MESHD which caused by SARS-CoV-2 has quickly spread across the world. Lymphopenia MESHD and a proinflammatory cytokine storm frequently happened in severe COVID-19 MESHD patients. But no specific immunomodulate therapy on COVID-19 MESHD had been reported. In this retrospect case control study, we observed the potential therapeutic effect of recombinant human i nterleukin-2 HGNC(rIL-2) on severe COVID-19 MESHD patients in a hospital in Wuhan, China. Methods: Fifty nine severe cases with COVID-19 MESHD admitted in hospital from January 29, 2020 to February 29, 2020 were included in this study. Twenty patients received a one-week to 10 days subcutaneous injection of the recombinant human interleulin-2 1 million IU per day other than regular treatment were classified as rIL-2 group. Twenty from thirty nine patients with regular treatment without intervention of rIL-2 were matched as the control group. Clinical characteristic such as age, gender, symptoms, signs, laboratory data and comorbidities were paired in these two groups. Changes of lymphocytes counts, I L-6 HGNCand C - reactive protein HGNC(C RP) HGNC before and after rIL-2 treatment and differences between rIL-2 group and non-rIL-2 group were analyzed.Results: There were a clearly visible increasing in lymphocyte counts and a decreasing in C RP HGNClevel in non rIL-2 group and rIL-2 group. The difference of the change of lymphocyte counts were significant in rIL-2 group and non-rIL-2 group (p<0.01). Though C RP HGNCdecreased more in rIL-2 group, it did not show a significant difference between the two groups (p>0.05).Conclusion: RIL-2 might be a prospective adjuvant therapy for severe COVID-19 MESHD patients by increasing lymphocytes number.

    Temporal clinical and laboratory response to interleukin-6 HGNC receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 MESHD pneumonia

    Authors: Daria S Formina; Mar'yana A Lysenko; Irina P Beloglazova; zinaida Y Mutinova; Nataliya G Poteshkina; Inna V Samsonova; Tat'yana S Kruglova; Anton A Chernov; Alexander V Karaulov; Michael M Lederman

    doi:10.1101/2020.06.12.20122374 Date: 2020-06-12 Source: medRxiv

    Abstract: Background:. Emerging evidence links morbidity and mortality of pandemic COVID-19 MESHD pneumonia MESHD to an inflammatory cytokine storm. Methods: Eighty nine patients with COVID-19 MESHD pneumonia MESHD and heightened systemic inflammation MESHD (elevated serum C reactive protein HGNC and interleukin-6 HGNC levels) were treated with Tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor HGNC. Results: Clinical and laboratory improvement was seen comparing baseline and 1-2 day post-infusion indices. Among 72 patients not receiving mechanical ventilation, NEWS2 scores fell from 5 to 2 (p <0.001) C reactive protein HGNC levels fell from 95 to 14 mg/L (p <0.001) and lymphocyte counts rose from 900 to 1000/uL (p=0.036). Sixty three of 72 patients were discharged from hospital, one patient died, and 8 remained in hospital at time of writing. Among 17 patients receiving mechanical ventilation, despite a rapid decrease in CRP HGNC levels from 89 to 35 mg/L (p = 0.014) and early improvements in NEWS2 scores in 10 of 17, ten patients died and seven remain in hospital at time of writing. Overall, mortality was only seen in patients who had markedly elevated CRP HGNC levels (>30 mg/L) and low lymphocyte counts (<1000/uL) before TCZ administration. Conclusions: Inflammation MESHD and lymphocytopenia MESHD are linked to mortality in COVID-19 MESHD. Inhibition of IL-6 HGNC activity by administration of Tocilizumab, an anti IL-6 receptor antibody is associated with rapid improvement in both CRP HGNC and lymphocyte counts and in clinical indices. Controlled clinical trials are needed to confirm the utility of IL-6 HGNC blockade in this setting. Additional interventions will be needed for patients requiring mechanical ventilation.

    Comparison of Clinical, Para-clinical and Laboratory Findings in Survived and Deceased Patients with COVID-19 MESHD: Diagnostic Role of Inflammatory Indications in Determining the Severity of Illness

    Authors: Mohsen Rokni; Kazem Ahmadikia; Somaye Asghari; Shahabodin Mashaei; Fahimeh Hassanali

    doi:10.21203/rs.3.rs-34994/v2 Date: 2020-06-12 Source: ResearchSquare

    Background: Since December 2019, when a cluster of pneumonia MESHD cases due to SARS-CoV-2 initially emerged in Wuhan city and then rapidly spread throughout the world, the necessity for data concerning the clinical and paraclinical features of Iranian patients with COVID-19 MESHD was highlighted. Therefore, we aimed to compare the clinical, paraclinical and laboratory evidences of deceased patients with survival group. Methods: We extracted data regarding 233 patients with laboratory-confirmed COVID-19 MESHD from Buali Hospital in Iran; clinical/paraclinical and inflammatory indexes data were collected and analyzed. The data of laboratory examinations and chest CT findings were compared between deceased and survived patients. Results: The mean age of the patients was 49.8 years and 64% of our patients were male. The acute respiratory distress syndrome MESHD occurred in 64 patients, 52 who were admitted to the ICU, which all of them underwent invasive mechanical ventilation, and 28 who died. Lymphopenia MESHD (79%), neutrophilia (79%), and thrombocytopenia MESHD (21%) were the most frequently observed laboratory findings of the deceased group on admission. Most patients (68%) had a high systematic immune-inflammation MESHD (SII) index of >500 and increased C-reactive protein HGNC level (88%). Levels of inflammatory indexes such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and SII were documented to be significantly elevated in the deceased group when compared with the patients who survived (P< 0.0001, P< 0.001, P< 0.0001, respectively). The most commonly presented symptoms were fever MESHD (70%) and cough MESHD (63%) on admission. Headache MESHD was uncommon (11%). Ground-glass opacity with consolidation (mixed) was the most common radiologic finding on chest CT (51%). No radiographic or CT abnormality was found in 15 of 204 patients (7%). Conclusion: Small fraction of patients with COVID-19 MESHD may present without fever MESHD and abnormal radiologic findings. Elevated NLR, PLR and SII can be considered as prognostic and risk stratifying factor of severe form of disease.

    Laboratory findings in coronavirus disease 2019 MESHD ( COVID-19 MESHD) patients: a comprehensive systematic review and meta-analysis

    Authors: Mohammad Karimian; Amirreza Jamshidbeigi; Gholamreza Badfar; Milad Azami

    doi:10.1101/2020.06.07.20124602 Date: 2020-06-08 Source: medRxiv

    Background: In early December 2019, the first patient with COVID-19 MESHD pneumonia MESHD was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19 MESHD. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 MESHD patients. Material and methods: The present meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. This protocol is registered with the code CRD42019145410 in PROSPERO International Database. Results: Finally, 52 studies involving 5490 patients with COVID-19 MESHD entered the meta-analysis process. The prevalence of leukopenia MESHD, lymphopenia MESHD, elevated c-reactive protein HGNC ( CRP HGNC), elevated erythrocyte sedimentation rate (ESR), elevated serum amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence of elevated interleukin-6 HGNC was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 HGNC was 62.0% (95%CI: 51.1-71.6), reduced CD8 HGNC was 42.7% (95%CI: 32.2-53.9). The prevalence of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide ( BNP HGNC) was 48.9% (95%CI: 30.4-67.7), elevated blood urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia MESHD was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6). Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19 MESHD. The results show that lymphopenia MESHD, elevated CRP HGNC, elevated ESR, elevated ferritin, elevated serum amyloid A, elevated BNP HGNC, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4 HGNC, reduced CD8 HGNC, elevated D-dimer, reduced PT, elevated interleukin-2 HGNC, elevated interleukin-6 HGNC, elevated LDH and hyperglycemia MESHD are the common findings at the time of admission.

    Low albumin levels are associated with poorer outcomes in a case series of COVID-19 MESHD patients in Spain: a retrospective cohort study

    Authors: Roberto de la Rica; Marcio Borges; Maria Aranda; Alberto del Castillo; Antonia Socias; Antoni Payeras; Gemma Rialp; Lorenzo Socias; Lluis Masmiquel; Marta Gonzalez-Freire

    doi:10.1101/2020.05.07.20094987 Date: 2020-05-11 Source: medRxiv

    OBJECTIVE To describe the clinical characteristics and epidemiological features of severe (non-ICU) and critically patients (ICU) with COVID-19 MESHD at triage, prior hospitalization, in one of the main hospitals in The Balearic Islands health care system. DESIGN Retrospective observational study SETTING Son Llatzer University Hospital in Palma de Mallorca MESHD (Spain) PARTICIPANTS Among a cohort of 52 hospitalized patients as of 31 March 2020, 48 with complete demographic information and severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) positive test, were analyzed. Data were collected between March 15th, 2020, and March 31th 2020, inclusive of these dates. MAIN OUTCOMES Clinical, vital signs and routine laboratory outcomes at the time of hospitalization, including symptoms reported prior to hospitalization. Demographics and baseline comorbidities were also collected. Mortality was reported at the end of the study. RESULTS 48 patients (27 non-ICU and 21 ICU) resident in Mallorca, Spain (mean age, 66 years, [range, 33-88 years]; 67% males) with positive SARS-CoV-2 infection MESHD were analyzed. There were no differences in age or sex among groups (p >.05). Initial symptoms included fever MESHD (100%), coughing (85%), dyspnea MESHD (76%), diarrhea MESHD (42%) and asthenia MESHD (21%). The majority of patients in this case series were hospitalized because of low SpO2 (SpO2 below 90%) and presentation of bilateral pneumonia MESHD (94%) at triage. ICU patients had a higher prevalence of dyspnea MESHD compared to non-ICU patients (95% vs 61%, p = .022). Acute respiratory syndrome MESHD ( ARDS MESHD) was presented in 100% of the ICU-patients. All the patients included in the study required oxygen therapy. ICU-patients had lymphopenia MESHD as well as hypoalbuminemia MESHD. Inflammatory markers such as lactate dehydrogenase (LDH), C-reactive protein HGNC ( CRP HGNC), and procalcitonin were significantly higher in ICU patients compared to non-ICU (p < .001).Lower albumin levels were associated with poor prognosis measured as longer hospital length (r= -0.472, p

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.